Entries by Maren Kühr

Successor found for CEO

Sana Alajmovic has been appointed as the new CEO of the Swedish company Enzymatica AB by the Board of Directors. The current CEO, Claus Egstrand, will become a member of the Board.

Experienced immunologist as CMO

Immunotherapy company Centauri Therapeutics Ltd, based in Alderley Park, Cheshire, UK, has announced the appointment of Dr Debra Barker as Chief Medical Officer (CMO).

New managing director takes over

UK-based contract research, development and manufacturing organisation (CRDMO) Arcinova announced the appointment of Dr Christian Dowdeswell as its new managing director at the beginning of August. Co-founder and CEO Paul Ryan steps down.

It is time to rethink biotech scaling

Biomanufacturing promises domestic, sustainable, sovereign and resilient production. Capacities are trapped in outdated scale-up processes. SPRIND urges investment and disruptive innovation to propel biomanufacturing. Demands are decentralised, non-sterile & continuous biomanufacturing capabilities.

Spain’s biotech: growth, impact and global role

Spain’s biotech sector drives innovation, economic growth, and scientific ­excellence. With strong R&D investment, global research impact, and a leading role in gender equality, it’s a key player in health, sustainability, and strategic autonomy. BIOSPAIN 2025 in Barcelona will showcase its potential and connect global biotech leaders.

Enzymatica CEO steps down

The CEO of Lund-based Enzymatica AB, Claus Egstrand, is stepping down from his role. CFO Therese Filmersson will also leave her position. The process of finding their successors has already begun.

Unlocking Pichia for industry

Pichia pastoris (syn. Komagataella phaffii), a methylotrophic yeast, is a proven platform for pharmaceutical protein production. However, its potential reaches far beyond. As a reliable, scalable, and cost-efficient platform for recombinant protein expression, Pichia is equally suited for industrial enzymes, food & feed, diagnostics, and biomaterials.

Ensuring flexibility and resilience

In today’s rapidly evolving world, adapting to demand volatilities while ­ensuring uninterrupted supply of biological medicines is more critical than ever. At ­Boehringer Ingelheim, our global biopharmaceutical network delivers flexibility, resilience, and ­reliability. By leveraging harmonised procedures, standardised setups, and innovative logistics, we ­ensure the biologics we produce reach those in need – even during unexpected challenges.

US health care sector: rising demand with uncertainty

In addition to the uncertainty triggered by the US government with serious changes at the FDA and other healthcare institutions and an unclear stance of the US Secretary of Health and Human Services on various areas of innovation, the growing demand for health care services gives a positive momentum that can provide stability.